Multiple Myeloma Clinical Trial

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

18 years and older'
diagnosed with active R/RMM, who have failed 2 lines of treatment
have measurable disease

Exclusion Criteria:

- Patients with active plasma cell leukemia

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT05113342

Recruitment Status:

Recruiting

Sponsor:

Cartesian Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Louisiana State University Health Science Center at Shreveport
Shreveport Louisiana, 71103, United States More Info
Tamna Wangjam, M.D.
Principal Investigator
Center for Cancer and Blood Disorders
Bethesda Maryland, 20817, United States More Info
Investigator
Contact
Medical College of Wisconsin
Madison Wisconsin, 53226, United States More Info
Nicole Raykovich
Contact
Binod Dhakal, MD
Principal Investigator
Saglik Bilimleri Universitesi
Ankara Anatolia, 06200, Turkey More Info
Fevzi Altuntas, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT05113342

Recruitment Status:

Recruiting

Sponsor:


Cartesian Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.